Table 109Median treatment ranking (with their 95% CrI) of all interventions in the network and the probability of being the best treatment for reducing the number of people experiencing at least one exacerbation with short-term (410 weeks) treatment

Median (95% CrI) treatment rankProbability of being the best treatment (%)
Placebo3 (2–4)0.70%
Aztreonam lysine1 (1–2)88.30%
Tobramycin (nebulised)4 (2–4)1.00%
Tobramycin + Fosfomycin (nebulised)2 (1–4)10.00%

From: 9, Pulmonary monitoring, assessment and management

Cover of Cystic Fibrosis
Cystic Fibrosis: Diagnosis and management.
NICE Guideline, No. 78.
National Guideline Alliance (UK).
Copyright © NICE 2017.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.